Oramed Pharmaceuticals Chosen to Present Results of GLP-1 Analog Enteral Administration Study at the Diabetes Technology Society's Eighth Annual Meeting (November 13-15, 2008; Bethesda, Maryland)
JERUSALEM, November 04, 2008 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals, Inc. (http://www.oramed.com), a developer of proprietary drug delivery systems, announced today that its poster entitled "Enteral Administration of Exenatide-4; Proof of Concept Pharmacodynamic Study in Dogs," has been accepted for presentation at the Diabetes Technology Society's Eighth Annual Meeting in Bethesda, Maryland between November 13-15, 2008.
Oramed's exploratory study of enteral delivery of GLP-1 analog, exenatide-4, an incretin mimetic with antihyperglycemic actions on dogs, advances research in the area of enteral delivery of polypeptides and proteins. Oramed's test results showed that direct instillation of GLP-1 analog significantly curbed post-glucose loading, demonstrating the feasibility of administering the drug enterally.
"The selection of Oramed as one of the companies to present at the Diabetes Technology Conference is a wonderful opportunity for us to demonstrate our revolutionary technology to the world's leading diabetes scientists," said Nadav Kidron, Oramed CEO. "We are very proud that our research is advancing the treatment of diabetes and we look forward to continuing to present strong results from the studies and trials we are currently conducting."
Oramed's abstract will be presented on Thursday, November 13, from 6-8 PM. The poster will be available for viewing throughout the conference.
For more information about the Diabetes Technology Society's Eighth Annual Meeting, please visit http://www.diabetestechnology.org/index.html
For more information about Oramed Pharmaceuticals, please visit http//www.oramed.com
About Oramed Pharmaceuticals
Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed is seeking to revolutionize the treatment of diabetes through its patented flagship product, an orally ingestible insulin capsule currently in phase 2 clinical trials. Established in 2006, Oramed's technology is based on over 25 years of research by top research scientists at Jerusalem's Hadassah Medical Center. The Company's corporate and R&D headquarters are based in Jerusalem.
For more information, please visit http://www.oramed.com
Some of the statements contained in this press release are forward-looking statements which involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for our product candidates; competition from other pharmaceutical or biotechnology companies; and the company's ability to obtain additional funding required to conduct its research, development and commercialization activities. Please refer to the company's filings with the Securities and Exchange Commission for a comprehensive list of risk factors that could cause actual results, performance or achievements of the company to differ materially from those expressed or implied in such forward looking statements. The company undertakes no obligation to update or revise any forward-looking statements.
Company and Investor Relation Contacts: Oramed Pharmaceuticals Eric Rosenberg Cell: +972-54-566-7713 Office: +972-2-566-0001 Email: firstname.lastname@example.org Media Contacts: Ruder Finn Israel for Oramed Matthew Krieger Cell: +972-54-467-6950 Office: +972-2-589-2003 Email: email@example.com
CONTACT: Company and Investor Relation Contacts: Oramed Pharmaceuticals,Eric Rosenberg, Cell: + 972-54-566-7713, Office: + 972-2-566-0001, Email:; Media Contacts: Ruder Finn Israel for Oramed, MatthewKrieger, Cell: + 972-54-467-6950, Office: + 972-2-589-2003, Email: firstname.lastname@example.org email@example.com
Ticker Symbol: (NASDAQ-OTCBB:ORMP),(NASDAQ-OTCBB:ORMP)
Terms and conditions of use apply
Copyright © 2008 PR Newswire Association LLC. All rights reserved.
A United Business Media Company
Posted: November 2008